论文部分内容阅读
动物源性皮肤利什曼病已经成为突尼斯中部农村的严重公共卫生问题。葡甲胺锑仍是目前治疗此病首选药物。但此药价高且需反复注射,并可出现副反应,因而WHO未推荐作治疗药,仅用于损害多发及位于面部或经久不愈时。1963年起单霉素类就用于皮肤利什曼病的治疗;最近,属于同类抗生素的巴龙霉素亦用于该病的治疗。本文报告采用双盲、随机和服用安慰剂的方法评价巴龙霉素对皮肤利什曼病的疗效。
Animal-derived cutaneous leishmaniasis has become a serious public health problem in rural Tunisia. Meglumine antimony is still the drug of choice for the treatment of the disease. However, this drug is expensive and requires repeated injections, and side effects can occur, so WHO is not recommended for treatment of drugs, only for the damage to multiple and located in the face or prolonged unhealed. Monomers have been used for the treatment of cutaneous leishmaniasis since 1963; paromomycins, which belong to the same class of antibiotics, have also been used recently for the treatment of cutaneous leishmaniasis. This article reports the efficacy of paromomycin on cutaneous leishmaniasis in a double-blind, randomized, and placebo-controlled fashion.